These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 8267904

  • 1. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM.
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D.
    J Hum Virol; 2001 Oct; 4(6):306-16. PubMed ID: 12082397
    [Abstract] [Full Text] [Related]

  • 3. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
    Klein MR, Veenstra J, Holwerda AM, Roos MT, Gow I, Patou G, Coutinho RA, De Wolf F, Miedema F.
    AIDS Res Hum Retroviruses; 1997 Mar 20; 13(5):393-9. PubMed ID: 9075480
    [Abstract] [Full Text] [Related]

  • 4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 20; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
    Weber J, Cheinsong-Popov R, Callow D, Adams S, Patou G, Hodgkin K, Martin S, Gotch F, Kingsman A.
    Vaccine; 1995 Jun 20; 13(9):831-4. PubMed ID: 7483805
    [Abstract] [Full Text] [Related]

  • 6. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
    O'Toole CM, Lowdell MW, Chargelegue D, Colvin BT.
    AIDS Res Hum Retroviruses; 1992 Aug 20; 8(8):1361-8. PubMed ID: 1281655
    [Abstract] [Full Text] [Related]

  • 7. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A.
    Biopolymers; 2004 Aug 20; 76(4):334-43. PubMed ID: 15386266
    [Abstract] [Full Text] [Related]

  • 8. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.
    Mills KH, Kitchin PA, Mahon BP, Barnard AL, Adams SE, Kingsman SM, Kingsman AJ.
    J Immunol; 1990 Mar 01; 144(5):1677-83. PubMed ID: 1689753
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
    Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A.
    Cell Mol Biol (Noisy-le-grand); 1995 May 01; 41(3):401-7. PubMed ID: 7580834
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
    Tewari D, Notkins AL, Zhou P.
    J Gene Med; 2003 Mar 01; 5(3):182-9. PubMed ID: 12666184
    [Abstract] [Full Text] [Related]

  • 11. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J, Salvetti JL, Beltramini LM, Tonarelli G.
    Rev Argent Microbiol; 2004 Mar 01; 36(4):151-7. PubMed ID: 15786866
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team.
    J Infect Dis; 2001 Feb 15; 183(4):563-70. PubMed ID: 11170981
    [Abstract] [Full Text] [Related]

  • 13. [Expression and characterization of HIV-1 Gag p17-p24 protein].
    Li TY, Jin NY, Wang HW, Guo ZR, Fang HH, An RG, Yin Z.
    Sheng Wu Gong Cheng Xue Bao; 2000 Jan 15; 16(1):65-8. PubMed ID: 10883279
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R.
    Virology; 1997 Aug 18; 235(1):26-39. PubMed ID: 9300034
    [Abstract] [Full Text] [Related]

  • 15. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
    Broliden PA, Morfeldt-Månsson L, Rosen J, Jondal M, Wahren B.
    Clin Exp Immunol; 1989 May 18; 76(2):216-21. PubMed ID: 2503275
    [Abstract] [Full Text] [Related]

  • 16. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.
    Koup RA, Pikora CA, Luzuriaga K, Brettler DB, Day ES, Mazzara GP, Sullivan JL.
    J Exp Med; 1991 Dec 01; 174(6):1593-600. PubMed ID: 1744586
    [Abstract] [Full Text] [Related]

  • 17. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
    Veenstra J, Williams IG, Colebunders R, Dorrell L, Tchamouroff SE, Patou G, Lange JM, Weller IV, Goeman J, Uthayakumar S, Gow IR, Weber JN, Coutinho RA.
    J Infect Dis; 1996 Oct 01; 174(4):862-6. PubMed ID: 8843231
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J, Bojak A, Deml L, Wagner R.
    Vaccine; 2004 Apr 16; 22(13-14):1732-43. PubMed ID: 15068857
    [Abstract] [Full Text] [Related]

  • 20. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
    Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J.
    J Infect Dis; 1999 Aug 16; 180(2):290-8. PubMed ID: 10395842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.